CYP3A4*1B polymorphism and cancer risk: A HuGE review and meta-analysis
- 558 Downloads
CYP450 3A4 (CYP3A4), encoded by the CYP3A4 gene, is a major enzyme catalyzing the metabolism of both endogenous and exogenous agents that may play a role in the etiology of carcinogenesis. Several potentially functional polymorphisms of the CYP3A4 gene have been implicated in cancer risk, but individually published studies have shown inconclusive results. The aim of this Human Genome Epidemiology (HuGE) review and meta-analysis was to investigate the association between CYP3A4*1B (rs2740574 A > G) polymorphism and cancer risk. Eleven studies were included with a total of 3,810 cancer patients and 3,173 healthy controls. We found that the G allele and GG genotype of CYP3A4*1B polymorphism were associated with increased risk of cancers using the fixed effects model (allele model: odds ratio (OR) = 1.24, 95 %CI: 1.09–1.42, P = 0.001; recessive model: OR = 1.77, 95 %CI: 1.30–2.41, P < 0.001; homozygous model: OR = 1.72, 95 %CI: 1.19–2.47, P = 0.004). Subgroup analyses by cancer type showed that the G allele and G carrier (AG + GG) of CYP3A4*1B polymorphism had significant associations with increased risk of prostate cancer, but not with breast cancer, leukemia, or other cancers. With further subgroup analysis based on different ethnicities, the results indicated that the GG genotype of CYP3A4*1B polymorphism might increase the risk of cancer among African populations. However, similar associations were not observed among Caucasian and Asian populations. Results from the current meta-analysis indicate that the G allele and GG genotype of CYP3A4*1B polymorphism might be associated with increased cancer risk, especially for prostate cancer among African populations.
KeywordsCYP3A4 Polymorphism Cancer risk Meta-analysis
This study was supported by a grant from the Science and Technology Research Project of the Higher Education Department of Liaoning Province (No. L2010695).
Conflicts of interest
- 8.Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, Gaedigk A, Suver C, Zhong H, Leeder JS, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich RG, Slatter JG, Schadt EE, Kasarskis A, Lum PY. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res. 2010;20:1020–36.PubMedCrossRefGoogle Scholar
- 14.Voso MT, Fabiani E, D'Alo F, Guidi F, Di Ruscio A, Sica S, Pagano L, Greco M, Hohaus S, Leone G. Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2007;18:1523–8.CrossRefGoogle Scholar
- 22.Yuan XJ, Gu LJ, Zhao HJ, Tang JY, Xue HL, Chen J, Pan C, Chen J, Wang YP. Analysis of cytochrome p450 genotype polymorphism in chinese children with acute leukemia. J Appl Clin Pediatr. 2005;20:654–6.Google Scholar
- 24.Bolufer P, Collado M, Barragan E, Cervera J, Calasanz MJ, Colomer D, Roman-Gomez J, Sanz MA. The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica. 2007;92:308–14.PubMedCrossRefGoogle Scholar
- 27.McDaniel DO, Thurber T, Lewis-Traylor A, Berry C, Barber WH, Zhou X, Bigler S, Vance R. Differential association of cytochrome p450 3a4 genotypes with onsets of breast tumors in African American versus caucasian patients. Journal of investigative medicine: the official publication of the American Federation for Clinical Research. 2011;59:1096–103.Google Scholar
- 28.Inoue K, Inazawa J, Nakagawa H, Shimada T, Yamazaki H, Guengerich FP, Abe T. Assignment of the human cytochrome p-450 nifedipine oxidase gene (cyp3a4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization. The Japanese journal of human genetics. 1992;37:133–8.PubMedCrossRefGoogle Scholar
- 33.Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G, Witte JS. Association between a cyp3a4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1999;8:901–5.Google Scholar
- 35.Kadlubar FF, Berkowitz GS, Delongchamp RR, Wang C, Green BL, Tang G, Lamba J, Schuetz E, Wolff MS. The cyp3a4*1b variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2003;12:327–31.Google Scholar